Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on May 24, 2019, covering events occurring on May 24, 2019, and May 29, 2019. The company is an emerging growth company incorporated in Delaware, with its common stock trading on The Nasdaq Global Select Market under the symbol OCUL.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on corporate governance changes and regulatory developments.
Material Changes
- Executive Departure: Dr. Amarpreet S. Sawhney resigned as Chairman of the Board and all other officer/employee positions, effective July 26, 2019. A Transition Agreement was executed on May 29, 2019, covering the period until his separation date.
- Consulting Arrangement: Effective immediately following the separation date, Dr. Sawhney will provide scientific and technical consulting services on an hourly fee-for-service basis.
- Equity Treatment: Outstanding stock options granted to Dr. Sawhney will continue to vest during the transition and consulting periods, provided services continue. Vesting ceases upon termination of the consulting agreement.
- Regulatory Approval: The Centers for Medicare and Medicaid Services (CMS) approved transitional pass-through payment status and established a new reimbursement code (C9048) for the company's product DEXTENZA (dexamethasone ophthalmic insert), effective July 1, 2019.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future performance. However, it notes the following operational developments:
- Reimbursement Outlook: The C-code facilitates reimbursement for DEXTENZA in hospital outpatient and ambulatory surgical center settings until a permanent J-code is potentially approved. CMS preliminarily recommended DEXTENZA for a dedicated J-code in May 2019, which could become effective January 1, 2020.
- Contractual Risks: The Consulting Agreement may be terminated immediately upon material breach or for any reason with ten days' written notice. It also terminates automatically upon Dr. Sawhney's death, incapacity, or revocation of his release of claims.
Investor Verification Checklist
- Verify the effective date of the C9048 reimbursement code (July 1, 2019) and its impact on DEXTENZA commercialization.
- Monitor the status of the preliminary recommendation for the permanent J-code, with a potential effective date of January 1, 2020.
- Review the terms of the Transition and Consulting Agreements (Exhibits 10.1 and 10.2) regarding Dr. Sawhney's ongoing role and compensation.
- Confirm the timeline for the appointment of a new Chairman of the Board following Dr. Sawhney's departure.